Year: 2024
Type: article
Abstract: Background 124I-PU-H71 is an imaging biomarker of epichaperome formation, localizing in tissues under chronic stress. A first-in-human positron emission tomography (PET) trial in cancer patients revealed unexpected tracer accumulation in the myocardium. Results Myocardial accumulation of 124I-PU-H71 was prominent in all patients, with median LVmyo SUVmean of 2.8, 2.5, 2.4 and 1.0 at 1-9min, 14-23min, 3-4hrs and 21-25hrs, respectively. Myocardium uptake peaked within 2 minutes post-injection, remaining sustained after 4hrs post-injection. Uniform tracer uptake was observed in LV and myocardial segments; with LVEF of 57.7±3.5%; no patients suffered cardiac events over subsequent 12-month period. Conclusion PU-H71 PET merits further study as a myocardial epichaperome biomarker, with potential application in drug development, and as biomarker in subclinical cardiac dysfunction.
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: A chemical chaperomics platform for AD, Small molecule Hsp90 inhibitors in AD treatment, Biomarkers for predicting response to Hsp90 therapy, Selective interactome vulnerability across the Alzheimer’s disease spectrum, Cancer Center Support Grant, Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum, Chaperome networks in Alzheimer's disease, Neuropathology and inflammation in a nonhuman primate model of insulin resistance/metabolic syndrome, Selective interactome vulnerability across the Alzheimer’s disease spectrum
OpenAlex ID: W4402694347